Roche, Spark Therapeutics Acquisition Delayed Under Regulatory Review
Roche has extended its offering period for the purchase of Spark to provide US and UK regulatory authorities with additional time to complete their review of the acquisition.
On Sept. 3, 2019, Roche and Spark Therapeutics announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of Spark common stock for $114.50 per share. The offer was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, Sept. 3, 2019. This has been extended until 5:00 p.m., New York City time, on Tuesday, Oct. 1, 2019.
The offering was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA, Roche reports.
Closing of the tender offer is conditioned upon customary closing conditions.
Source: Roche
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
